Evidence map›Paper›PMID 39859577›Full record

ArticleInternational journal of molecular sciences2025

Design, Synthesis, Anticancer Screening, and Mechanistic Study of Spiro-N-(4-sulfamoyl-phenyl)-1,3,4-thiadiazole-2-carboxamide Derivatives.

Ahmed M El-Saghier, Hamada Hashem, Sherif A Maher, Souhaila S Enaili, Abdullah Alkhammash, Stefan Bräse, Hossameldin A Aziz

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. NovelPharmaceuticals (Basel, Switzerland) · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ahmed M El-SaghierDepartment of Chemistry, Faculty of Science, Sohag University, Sohag 82524, Egypt.ORCID 0000-0002-4338-1486
Hamada HashemDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag 82524, Egypt.ORCID 0000-0002-8649-7534
Sherif A MaherDepartment of Biochemistry, Faculty of Pharmacy, New Valley University, New Valley 72511, Egypt.
Souhaila S EnailiDepartment of Chemistry, Faculty of Science, University of Zawia, Az Zawiyah 16418, Libya.ORCID 0009-0006-4254-7137
Abdullah AlkhammashDepartment of Pharmacology, College of Pharmacy, Shaqra University, Shaqra 11961, Saudi Arabia.ORCID 0009-0002-2000-2620
Stefan BräseInstitute for Biological and Chemical System, Karlsruhe Institute of Technology, 76131 Karlsruhe, Germany.ORCID 0000-0003-4845-3191
Hossameldin A AzizDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, New Valley University, New Valley 72511, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aims to create spiro-N-(4-sulfamoyl-phenyl)-1,3,4-thiadiazole-2-carboxamide derivatives with anticancer activities. The in vitro anticancer evaluation showed that only the novel spiro-acenaphthylene tethered-[1,3,4]-thiadiazole (compound

Indexed as

Antineoplastic AgentsCarbonic Anhydrase InhibitorsDrug DesignThiadiazolesApoptosisCarbonic Anhydrase IXCarbonic AnhydrasesCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMolecular Docking SimulationStructure-Activity RelationshipAntineoplastic AgentsCarbonic Anhydrase InhibitorsCarbonic Anhydrase IXCarbonic AnhydrasesThiadiazolesanticancercarbonic anhydrases inhibitormolecular dockingthiadiazole

Identifiers

PMID39859577
PMCPMC11766273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.